Dr. Stanton C. Goldman
Claim this profileMedical City Dallas Hospital
Expert in Cancer
Expert in Neuroblastoma
56 reported clinical trials
104 drugs studied
About Stanton C. Goldman
Education:
- Earned an MD from Boston University School of Medicine in 1990.
- Completed Residency in General Pediatrics at Children's National Medical Center, Washington, D.C. (1990-1993).
- Undertook a Fellowship in Pediatric Hematology/Oncology at Johns Hopkins University Medical Center, Baltimore (1993-1996).
Experience:
- Board certified in Hematology-Oncology by the American Board of Pediatrics.
- Over 33 years of experience in Pediatrics, with affiliations to Medical City Dallas and Medical City Plano.
- Serves as the Principal Investigator for the Children's Oncology Group at Medical City Dallas and Chief Medical Officer for Medical City Children's Hospital.
- Authored over 30 articles and several book chapters on tumor lysis syndrome and pediatric mature B non-Hodgkin lymphoma.
Area of expertise
1Cancer
Global LeaderStage I
Stage IV
Stage II
2Neuroblastoma
Global LeaderMYC positive
Stage IV
MYC negative
Affiliated Hospitals
Clinical Trials Stanton C. Goldman is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Selinexor + Radiation
for Brain Cancer
This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
Recruiting1 award Phase 1 & 21 criteria
More about Stanton C. Goldman
Clinical Trial Related8 years of experience running clinical trials · Led 56 trials as a Principal Investigator · 19 Active Clinical TrialsTreatments Stanton C. Goldman has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Doxorubicin Hydrochloride
- Vincristine Sulfate
- Laboratory Biomarker Analysis
Breakdown of trials Stanton C. Goldman has run
Cancer
Neuroblastoma
Brain Tumor
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stanton C. Goldman specialize in?
Stanton C. Goldman focuses on Cancer and Neuroblastoma. In particular, much of their work with Cancer has involved Stage I patients, or patients who are Stage IV.
Is Stanton C. Goldman currently recruiting for clinical trials?
Yes, Stanton C. Goldman is currently recruiting for 19 clinical trials in Dallas Texas. If you're interested in participating, you should apply.
Are there any treatments that Stanton C. Goldman has studied deeply?
Yes, Stanton C. Goldman has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Stanton C. Goldman?
Apply for one of the trials that Stanton C. Goldman is conducting.
What is the office address of Stanton C. Goldman?
The office of Stanton C. Goldman is located at: Medical City Dallas Hospital, Dallas, Texas 75230 United States. This is the address for their practice at the Medical City Dallas Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.